Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093

MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib

Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates

Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting

First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial

CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng